ERA 2025 Highlights Podcast

In this podcast (10:19), Medicom’s correspondents discuss 6 presentations that were held at the 62nd Annual Meeting of the European Renal Association, held recently in Vienna: 

1. CANVAS trial showed that canagliflozin 300 mg reduced major cardiovascular events and all-cause mortality in type 2 diabetes; 100 mg did not. 


2. Empagliflozin meta-analysis on kidney disease progression slowed eGFR decline by 64% and reduced kidney disease progression risk by 30%, with stronger effects in patients with diabetes. 


3. CONFIDENCE trial: The combination of finerenone + empagliflozin in CKD and type 2 diabetes reduced albuminuria by 52% at 180 days, outperforming monotherapy. 


4. Acute eGFR dip and AKI risk with empagliflozin was not linked to higher risk of acute kidney injury; empagliflozin reduced AKI events by 27%.


5. ERA registry data on kidney transplantation survival benefit revealed that standard criteria donor transplants conferred a survival benefit over dialysis, regardless of recipient age or comorbidities; expanded criteria did not. 


6. VISIONARY trial: sibeprenlimab in IgA nephropathy reduced urinary protein/creatinine ratio by 51.2% over 9 months with a reassuring safety profile. 

Enjoy listening!

Copyright ©2025 Medicom Medical Publishers



Posted on 4 July 2025